» Articles » PMID: 25911179

Differential Toll-like Receptor Activation in Lung Ischemia Reperfusion Injury

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The requirement for toll-like receptors (TLRs) in lung ischemia reperfusion injury (LIRI) has been demonstrated but not fully characterized. Previously, we reported that TLR-4 is required by alveolar macrophages but not pulmonary endothelial or epithelial cells for development of LIRI. Additionally, we demonstrated differential patterns of mitogen-activated protein kinase (MAPK) activation and cytokine release in these cell types during LIRI. Here, we sought to determine whether these differences in activation responses are related to cell-specific TLR activation requirements.

Methods: Primary cultures of alveolar macrophages, pulmonary endothelial, and immortalized epithelial cells were pretreated with TLR-2 or TLR-4 short interference RNA (ribonucleic acid) before hypoxia and reoxygenation. Cell lysates and media were analyzed for receptor knockdown, MAPK activation, and cytokine production. Rats were pretreated with TLR-2 or TLR-4 short interference RNA before lung ischemia reperfusion and changes in lung vascular permeability were assessed.

Results: Knockdown of TLR-2 in alveolar macrophages did not affect MAPK phosphorylation or cytokine secretion. Conversely, TLR-2 knockdown in pulmonary endothelial and epithelial cells demonstrated significant reductions in extracellular signal-regulated kinase 1/2 activation and cytokine secretion. The lung permeability index in LIRI was decreased by TLR-4 but not TLR-2.

Conclusions: Differential TLR signaling and MAPK activation in response to LIRI seem to be cell specific. Short interference RNA provides an outstanding tool for examination of the underlying mechanism.

Citing Articles

Advances in lung ischemia/reperfusion injury: unraveling the role of innate immunity.

Li Q, Nie H Inflamm Res. 2024; 73(3):393-405.

PMID: 38265687 DOI: 10.1007/s00011-023-01844-7.


A Focused Review on Primary Graft Dysfunction after Clinical Lung Transplantation: A Multilevel Syndrome.

Van Slambrouck J, Van Raemdonck D, Vos R, Vanluyten C, Vanstapel A, Prisciandaro E Cells. 2022; 11(4).

PMID: 35203392 PMC: 8870290. DOI: 10.3390/cells11040745.


Lung Transplantation, Pulmonary Endothelial Inflammation, and Ex-Situ Lung Perfusion: A Review.

Forgie K, Fialka N, Freed D, Nagendran J Cells. 2021; 10(6).

PMID: 34200413 PMC: 8229792. DOI: 10.3390/cells10061417.


Systematic Understanding of Pathophysiological Mechanisms of Oxidative Stress-Related Conditions-Diabetes Mellitus, Cardiovascular Diseases, and Ischemia-Reperfusion Injury.

Wang M, Liu Y, Liang Y, Naruse K, Takahashi K Front Cardiovasc Med. 2021; 8:649785.

PMID: 33928135 PMC: 8076504. DOI: 10.3389/fcvm.2021.649785.


Ischemia-reperfusion Injury in the Transplanted Lung: A Literature Review.

Talaie T, DiChiacchio L, Prasad N, Pasrija C, Julliard W, Kaczorowski D Transplant Direct. 2021; 7(2):e652.

PMID: 33437867 PMC: 7793349. DOI: 10.1097/TXD.0000000000001104.


References
1.
Shimamoto A, Pohlman T, Shomura S, Tarukawa T, Takao M, Shimpo H . Toll-like receptor 4 mediates lung ischemia-reperfusion injury. Ann Thorac Surg. 2006; 82(6):2017-23. DOI: 10.1016/j.athoracsur.2006.06.079. View

2.
Angel L, Levine D, Restrepo M, Johnson S, Sako E, Carpenter A . Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes. Am J Respir Crit Care Med. 2006; 174(6):710-6. DOI: 10.1164/rccm.200603-432OC. View

3.
Favre J, Musette P, Douin-Echinard V, Laude K, Henry J, Arnal J . Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2007; 27(5):1064-71. DOI: 10.1161/ATVBAHA.107.140723. View

4.
Shigeoka A, Holscher T, King A, Hall F, Kiosses W, Tobias P . TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways. J Immunol. 2007; 178(10):6252-8. DOI: 10.4049/jimmunol.178.10.6252. View

5.
Wolf P, Merry H, Farivar A, McCourtie A, Mulligan M . Stress-activated protein kinase inhibition to ameliorate lung ischemia reperfusion injury. J Thorac Cardiovasc Surg. 2008; 135(3):656-65. DOI: 10.1016/j.jtcvs.2007.11.026. View